Published on
March 28, 2026
AML Compliance Challenges in Cross-Border M&A
Covers AML risks in cross-border M&A and practical steps—due diligence, UBO checks, sanctions screening, centralized tech, and tailored warranties.
Cross-border M&A deals face growing scrutiny over Anti-Money Laundering (AML) compliance. Failure to address these risks can derail transactions, lead to multi-million-dollar penalties, and damage reputations. Here's what you need to know:
- Why It Matters: New EU AML regulations impose fines of up to €10 million or 10% of annual turnover. Buyers risk inheriting liabilities from target companies, including sanctions and hidden ownership issues.
- Key Risks:
- Conflicting AML rules across jurisdictions.
- Exposure to high-risk regions with sanctions concerns.
- Complex ownership structures hiding illicit activities.
- Solutions:
- Conduct thorough due diligence, especially on beneficial ownership and tax records.
- Use centralized compliance tools and local expertise to navigate jurisdiction-specific rules.
- Include tailored warranties and indemnities in agreements to mitigate risks.
AML compliance is no longer optional in M&A. Early planning, robust screening, and expert guidance are essential to protect deal value and avoid regulatory pitfalls.
Key AML Compliance Risks and Statistics in Cross-Border M&A Transactions
Introducing AML Conversations – Technology, Compliance, and the Future of Financial Crime Prevention
sbb-itb-e766981
Key AML Risks in Cross-Border M&A
Cross-border M&A transactions come with three primary AML risks that can jeopardize deals and create long-term liabilities. Being aware of these risks is crucial to safeguard the transaction and maintain regulatory compliance.
Multi-Jurisdictional Transaction Complexity
Cross-border deals often involve navigating a maze of conflicting regulations across different countries. Each jurisdiction has its own AML rules, enforcement priorities, and reporting requirements. What may be acceptable in one country could result in serious violations in another.
Failing to address these regulatory differences can lead to hefty penalties. For instance, in 2014, cross-border healthcare M&A transactions hit $178 billion, yet 33% of executives admitted they lacked adequate pre- and post-deal planning to handle regulatory risks [2][3]. Emerging markets amplify these challenges, with shifting regulations and politically influenced legal frameworks. Tax evasion is a common warning sign of deeper money laundering issues. In some developing markets, companies avoid social security contributions by paying employees "off the books" or misclassifying workers. Such practices create hidden liabilities, including unpaid taxes, penalties, and sanctions, which buyers inherit after closing the deal.
Jane Hobson, Chair of Baker & McKenzie's Global Life Sciences Industry Group, emphasizes the importance of thorough tax diligence:
"The next big risk is whether the target has paid all its taxes or whether it has been paying them on a wrong basis. So you have to go through a big tax diligence, including whether there may be money laundering issues." [3]
Christian Lopez-Silva, Chair of Baker & McKenzie's Life Sciences Industry Group in Mexico, adds:
"Many buyers have learned the hard way that failing to account for regulatory differences can prevent them from closing in certain countries and keep them from achieving the original goal of the transaction." [3]
Operating in high-risk jurisdictions only adds to these complications.
High-Risk Jurisdictions and Sanctions Evasion
Acquiring companies in high-risk regions exposes buyers to sanctions risks that can significantly reduce deal value. Even minor compliance missteps can lead to immediate penalties or operational restrictions.
The "pharmerging" markets - 21 countries including China, Brazil, India, and Russia - offer substantial growth potential. Between 2012 and 2017, pharmaceutical sales in these markets were projected to grow 13%, compared to just 2% in mature markets [3]. However, these regions also carry the highest AML and sanctions risks due to evolving regulations and frequent interactions between private companies and government officials.
Vanina Caniza, Chair of Baker & McKenzie's Life Sciences Industry Group in Argentina, highlights the difficulty:
"What's harder than anything when doing transactions in emerging markets is the ever-changing and often contradictory legal framework and political situation." [3]
In such environments, legal compliance today may not guarantee immunity from retroactive sanctions tomorrow, as political shifts often dictate enforcement. Buyers also risk damaging their global regulatory relationships when acquiring entities with sanctions-related issues, even if those violations occurred under the seller's control. Once fines and penalties become public, the buyer’s reputation is inevitably impacted [1].
These risks are further compounded by challenges in identifying beneficial ownership.
Hidden Beneficial Ownership Structures
Opaque ownership structures, often involving shell companies, obscure the true stakeholders and increase AML risks. In regions like Latin America, family-owned businesses frequently rely on outdated and non-transparent ownership arrangements [3].
The situation becomes even riskier when Politically Exposed Persons (PEPs) are involved. In pharmerging markets, the close ties between private businesses and government officials create opportunities for corruption. Beneficial owners often use complex structures to hide improper relationships, particularly in companies that rely heavily on public tenders or third-party distributors [3].
Thorough tax diligence can help uncover hidden ownership and associated AML risks. In some cases, product registrations tied to specific entities or individuals may require re-registration during ownership changes, which can reveal concealed stakeholders [3].
Without harmonized regulations across jurisdictions, structures that are legal in one country may be designed specifically to bypass AML requirements elsewhere [2][3]. Buyers who overlook these arrangements inherit not only financial liabilities but also operational restrictions that can disrupt the target’s business model. These restrictions may limit market access or hinder client acquisition, fundamentally altering the company’s value and growth potential [1].
International AML Framework Differences
Navigating anti-money laundering (AML) compliance during cross-border mergers and acquisitions (M&A) is no small feat. The absence of consistent AML standards across countries makes it tricky for buyers to align practices. What’s considered compliant in one jurisdiction might be a serious violation in another. This forces buyers to juggle conflicting rules and highlights the need for a tailored post-deal integration strategy.
Regional AML Standard Variations
Although the Financial Action Task Force (FATF) offers international recommendations, how these guidelines are enforced varies significantly. For instance, the U.S. Financial Crimes Enforcement Network (FinCEN) emphasizes customer due diligence and transparency regarding beneficial ownership. In contrast, the European Union (EU) takes a risk-based approach to enforcement, backed by stricter penalties. Under the EU's new AML Regulation, non-compliance fines can reach €10 million or 10% of the total annual group turnover - whichever is higher. This means even a small subsidiary’s violation could lead to fines calculated on the entire corporate group’s revenue [1].
Strategic buyers face the challenge of bridging the "integration gap" between their own AML policies and those of the target company. Post-closing, buyers often discover that the target’s practices don’t align with their stricter standards - particularly when longer look-back periods or lower materiality thresholds are required. Adding to this complexity, the European Banking Authority (EBA) is introducing new classification metrics for breaches. These metrics may result in more violations being labeled as "serious", which could lead to higher penalties [1].
As regulatory inconsistencies linger, the introduction of new rules only raises the stakes for M&A compliance efforts.
New AML Regulations and Their Effects
Evolving AML regulations are reshaping how M&A deals are structured and executed. Centralized enforcement is making AML compliance a critical factor in deal-making. According to Freshfields, "Strategic investors value their market reputation and regulatory relationships, and acquiring a business with severe AML risks could jeopardise both" [1].
These developments add to the already complex due diligence process, making precise risk assessments essential. In Warranty and Indemnity (W&I) insurance transactions, AML risks are typically excluded, pushing buyers to negotiate specific warranties or indemnities directly with sellers. Buyers are increasingly demanding remediation plans as pre-closing conditions in Sale and Purchase Agreements (SPAs). For risks that can’t be quantified - like pending sanctions - buyers often require indemnities to ensure the seller covers future losses, including regulatory fines. Additionally, sellers are now requesting "conduct rights" in SPAs. This allows them to retain some control over how the target handles regulatory litigation tied to pre-closing breaches.
These shifts underscore how AML compliance is no longer just a regulatory box to check - it’s a key factor that can make or break a deal.
Due Diligence Gaps in Cross-Border M&A
Tight deadlines, scattered data, and varying regulations often create gaps in due diligence, leaving buyers exposed to anti-money laundering (AML) risks. Many executives admit to insufficient planning both before and after deals, which can lead to regulatory fines, damage to reputation, or even failed transactions.
Beneficial Ownership Verification
Identifying ultimate beneficial ownership (UBO) is a critical step, as complex ownership structures can hide money laundering activities. Regulators enforce the "look-through" principle, requiring buyers to trace ownership back to UBOs and verify the origin of their wealth. This process should also include screening board members, executives, and shareholders holding 10–25% stakes.
Another risk to consider is "Sanctions by Association", where a target company might not be directly sanctioned but is owned or controlled by a sanctioned entity. Failing to verify ownership thoroughly can result in integrating illicit funds, potentially leading to severe regulatory penalties. These steps are essential to tackle broader AML risks and ensure compliance.
Once ownership is clarified, the next challenge is consolidating data for a unified AML approach.
Data Integration Challenges
Jurisdictional differences and fragmented data systems often complicate AML assessments. In rapidly growing markets, high staff turnover makes it even harder to gather historical compliance data. Christian Lopez-Silva, Chair of Baker & McKenzie's Life Sciences Industry Group in Mexico, highlighted:
"The achievement of your M&A goals is often determined by the regulatory possibilities" [3].
To address these challenges, buyers should establish centralized governance structures while collaborating with local teams to navigate specific regulatory requirements [2]. Early data mapping helps prioritize jurisdictions with complex regulations. If time constraints prevent thorough pre-closing due diligence, a strong post-acquisition integration plan becomes critical [3]. Jane Hobson, Chair of Baker & McKenzie's Global Life Sciences Industry Group, noted:
"Companies have to do the appropriate level of due diligence and have a day one plan for addressing any concerns to be able to satisfy the authorities if there's an ABAC compliance problem found post-closing" [3].
For liabilities like unpaid social security contributions or hints of tax evasion that can't be fully quantified, placing part of the purchase price in escrow can safeguard against future penalties [3].
Once data is consolidated, the focus shifts to rigorous screening and ongoing monitoring.
Screening and Monitoring Requirements
AML compliance requires screening against international databases, including OFAC, EU, UN, and local lists, to identify politically exposed persons (PEPs), sanctioned entities, or other red flags. AI-powered tools are particularly effective at scanning global news and adverse media for signs of bribery or corruption. Advanced matching algorithms can manage variations in names, transliterations, and aliases, which are common in cross-border transactions.
Continuous monitoring throughout the deal lifecycle is essential to detect changes in a target's risk profile before closing. Integrating AML screening tools with Virtual Data Rooms (VDRs) automates the vetting process as new participants enter the deal. Keeping detailed records of all screening activities, including the rationale for clearing false positives, demonstrates good faith compliance to regulators. These actions not only protect buyers from regulatory scrutiny but also help maintain the overall value of the deal while ensuring adherence to evolving AML standards.
Solutions for AML Compliance in Cross-Border M&A
Risk-Based AML Frameworks
A risk-based approach tailors compliance measures to the specific risks of each transaction, such as interactions with government entities, reliance on third parties, or weak internal policies. For instance, frequent participation in public tenders or dependence on subjective regulatory approvals can serve as red flags.
To tackle this, centralized governance paired with local execution is crucial. This setup ensures consistent oversight while allowing local teams to address jurisdiction-specific requirements. For fast-paced transactions, like auction sales, buyers should allocate the first year post-closing to conduct thorough investigations and establish formal compliance policies. Vanina Caniza, Chair of Baker & McKenzie's Life Sciences Industry Group in Argentina, highlighted the importance of this:
"I've seen deals fall through because the target company didn't have adequate compliance standards in areas such as employment, tax and regulatory matters" [3].
Buyers can protect themselves with contractual safeguards, such as tailored representations, warranties, and indemnity clauses. Moreover, training senior management and sales teams in the target company is key, especially in regions where compliance programs may be underdeveloped.
Once risks are clearly identified, technology plays a pivotal role in ensuring consistent monitoring and addressing compliance issues across different regions.
Technology for AML Compliance
Centralized compliance platforms simplify the monitoring process across various jurisdictions while empowering local teams to handle execution. A data-driven approach is essential: this involves collecting all necessary company and regulatory data, forming regional teams, and managing the process centrally while executing locally.
Advanced screening tools are invaluable for assessing financial risks tied to non-compliance, such as unpaid taxes or social security contributions. The high volume of cross-border deals underscores the need for technology-driven integration plans to promptly address compliance gaps. This is especially critical in industries like pharmaceuticals, where staff turnover can exceed 20% [3].
Working with AML Experts
While frameworks and technology lay the groundwork, partnering with local experts refines compliance strategies. These advisors provide insights into local practices that may differ from written laws. They can identify high-risk government authorities, suspicious product registrations, or licenses granted under questionable discretionary authority. Christian Lopez-Silva, Chair of Baker & McKenzie's Life Sciences Industry Group in Mexico, explained:
"The achievement of your M&A goals is often determined by the regulatory possibilities" [3].
Phoenix Strategy Group (https://phoenixstrategy.group) offers specialized M&A advisory services to help growth-stage companies navigate the complexities of cross-border transactions. Their expertise in financial due diligence and strategic planning aids buyers in assessing compliance risks and crafting effective post-closing strategies.
Experts also assist in managing bureaucratic hurdles and local filing requirements, helping to predict realistic timelines for deal closures. Tracy Wut, Co-Chair of Baker & McKenzie's Global Life Sciences Industry Group in China and Hong Kong, emphasized:
"The buyer may need to educate the target's management on the importance of compliance from the start, and target problem areas quickly" [3].
Conclusion
Cross-border M&A transactions come with a unique set of AML challenges that can threaten the success of a deal. Whether it’s dealing with complex regulatory frameworks across multiple jurisdictions or uncovering concealed ownership structures, buyers often inherit risks such as money laundering or tax evasion. The stakes are considerable - 33% of global executives have pointed to the need for stronger pre- and post-deal planning as a critical takeaway from past cross-border M&A experiences [2].
Starting compliance planning early is a key step toward ensuring a smooth transaction. By setting up local and regional compliance teams before the deal closes, companies can establish AML monitoring and reporting systems right from day one. This approach minimizes the risk of unexpected regulatory hurdles that could lead to forced divestitures years down the line [3].
Addressing these risks requires a combination of targeted measures. A risk-based strategy, paired with advanced technology and expert insights, provides a solid foundation against AML issues. Centralized monitoring tools help keep track of activities across jurisdictions, while local expertise is invaluable for identifying suspicious patterns and assessing liabilities. This allows buyers to adjust deal valuations or include protective clauses in agreements, safeguarding their interests.
For growth-stage companies, navigating these challenges successfully often hinges on leveraging specialized M&A advisory services. As regulatory landscapes grow increasingly intricate, embedding compliance planning into every phase - from due diligence to post-closing - is crucial. Partnering with seasoned advisors like Phoenix Strategy Group equips businesses with the tailored support they need to tackle these obstacles methodically and avoid costly missteps.
FAQs
What AML red flags should make me pause a cross-border acquisition?
When it comes to cross-border acquisitions, certain warning signs can indicate potential anti-money laundering (AML) risks. These include:
- Connections to high-risk jurisdictions: Transactions involving countries with weak AML regulations or known financial crime issues should raise concern.
- Complex corporate structures: The use of shell companies or intricate ownership arrangements can be a red flag, as they may be designed to obscure the true ownership or origin of funds.
- Unusual payment behaviors: Irregularities like payments made through third parties, unexpected changes in payment methods, or transfers that don’t align with the business purpose are worth investigating.
- Evidence of structuring or layering: Techniques aimed at concealing illicit funds, such as breaking down large transactions into smaller ones or routing money through multiple accounts, are key indicators.
Identifying and addressing these red flags is crucial for mitigating compliance risks and ensuring thorough due diligence during cross-border deals.
How can I verify the target’s ultimate beneficial owners across multiple countries?
To identify ultimate beneficial owners (UBOs) across different countries, consider using advanced RegTech tools that incorporate AI, blockchain technology, and automated workflows. These solutions simplify the Know Your Customer (KYC) process and sanctions screening, helping businesses stay compliant with both local and international regulations.
Automated Anti-Money Laundering (AML) systems take it a step further by revealing hidden ownership layers. They achieve this by analyzing data from public registries, corporate databases, and financial records, improving due diligence efforts and minimizing the risks of money laundering.
What AML protections should be included in the SPA if insurance won’t cover them?
If insurance doesn’t cover AML protections in the SPA, it’s important to include specific provisions to safeguard the transaction. These might include detailed due diligence requirements, representations and warranties confirming AML compliance, covenants for ongoing AML monitoring, and indemnities for breaches of AML obligations. Together, these measures help reduce risks and maintain compliance throughout the deal.
